|
Post by otherottawaguy on May 7, 2015 20:19:33 GMT -5
what was the interest rate Sanofi was charging vs what credit from the street would cost? If Sanofi rate is lower, it a no brainer. Did I see that they got another 50M milestone, or was that the previous one?
OOG
|
|
|
Post by otherottawaguy on May 7, 2015 18:29:28 GMT -5
thanks, will try it later, I am back home now.
OOG
|
|
|
Shoutbox
May 7, 2015 17:40:10 GMT -5
via mobile
Post by otherottawaguy on May 7, 2015 17:40:10 GMT -5
On the mobile. Did the earnings release happen or was it delayed?
|
|
|
Post by otherottawaguy on May 5, 2015 16:09:31 GMT -5
Wonder if we have enough stats lying around to produce our own graphic? One that shows afrezza as well.
With a caption that looks like an after thought talking about it being an inhaled option.
|
|
|
Post by otherottawaguy on May 5, 2015 15:57:48 GMT -5
They didn't show a timeline on the second graph, be interested to see how Afrezza would snuggle inside the other three curves.
OOG
|
|
|
Post by otherottawaguy on May 4, 2015 15:08:23 GMT -5
Staying at Ethan Allan.
Where are we getting together before the meeting?
OOG
|
|
|
Post by otherottawaguy on Apr 30, 2015 9:08:26 GMT -5
MannKind Afrezza Contributes to Sanofi's Subpar Diabetes Unit Sales By Adam Feuerstein Follow | 04/30/15 - 06:51 AM EDT
PARIS (TheStreet) -- Sales of MannKind's (MNKD) inhaled insulin Afrezza totaled €1 million in the first quarter of its commercial launch, marketing partner Sanofi (SNY - Get Report) reported Thursday. Afrezza sales reported by Sanofi presumably includes inventory stocking, but the company did not break down the results further. Sanofi began selling Afrezza in early February.
In today's dollars, Afrezza sales were just over $1.1 million in the quarter, well below the MannKind analyst consensus target in the range of $3 million to $4 million. The Afrezza sales miss was anticipated, however, based on generally weak prescription numbers compiled by tracking services like IMS Health.
Asked to assess the nascent Afrezza launch, a Sanofi spokesperson said, "The initial rollout of Afrezza is targeted and focused on building awareness behind the product and appropriate usage. Because of requirements imposed by the FDA for starting patients on this therapy and the necessary time to gain market access, it will take time for Afrezza to demonstrate its potential. Additional activities planned for 2015 include a direct-to-consumer campaign and the launch of the 12-unit cartridge planned for the second half of 2015."
Sanofi's total diabetes sales were €1.84 billion in the quarter, a decrease of 3.2% from the previous year. The company said diabetes sales would likely fall approximately 3% for the remainder of the year due to competition and pricing pressure in the U.S. Previously, Sanofi expected sales in its diabetes unit to remain "broadly stable" in 2015.
Sales of the insulin product Lantus, Sanofi's biggest, fell 5% to €1.6 billion, reflecting lower sales in the U.S. Lantus loses patent protection later this year. Sales of newly launched insulin Toujeo were €7 million.
Overall, Sanofi earnings in the first quarter rose 2.6% on a constant basis, or almost 13% when favorable currency exchange rates are factored in. Sales rose 2.4% on a constant basis, or 12.3% with currency factored in. The company's results exceeded analyst expectations.
|
|
|
Post by otherottawaguy on Apr 28, 2015 11:22:21 GMT -5
Looking for some feedback here.
Gomnkd pointed out some line capacity numbers the other day and I have even seen references to numbers from Matt that support his production levels.
To date, I have been using the old numbers based upon max plant capacity given by Dr Mann. As he and others in the more distant past that Danbury was capable of supporting 2 Million annual users, via the physical foot print capable of holding 12 production lines,
The math on this one: 2,000,000 / 12 = 166,666 annual script per line. Using this number of 166k and assuming 3 dosages per day * 364 days: 166666*3*364 = 182,000,000 Cartridges per year.
In an interim interview, Matt stated that the new machines were capable of about 10% more output that Line 1 or about 200M cartridges annually.
For a net current capacity of 580M cartridges.
My problem with this number, arises in that in very recent interview (purported interview), Matt has now said that the number possible is 110M cartridges for Line 1 and about 120M for line 2. (The lower numbers are what Gomnkd was suggesting and I have seen other references to it on YMB).
This really screws up calcs for the Demand vs Capacity curves so I would like to get a reference to a firm source that tells us the true capacity of a Line (old and newer).
When working with these possibly lower numbers and increased usages that are being reported, it will not take as long for capacity to exceed demand.
Thanks,
OOG
|
|
|
Post by otherottawaguy on Apr 27, 2015 14:42:18 GMT -5
Someone the other day was mentioning that those that have an account, can actually drill down in the on line report where they can view the status of their shares in the lending program and see how many are avail overall in the pool avail for lending. Wondering if this could be used as the proverbial "Canary in a Coal Mine" on days like today and if it could actually be monitored intra day? If intra day we might see the turn for those looking to catch the knife before it hits the ground and bounces.
OOG
|
|
|
Post by otherottawaguy on Apr 27, 2015 14:01:20 GMT -5
Wondering if might be possible for anyone whom has access, to give us the current Shares Avail and what Fidelity is charging.
Be interested to know if there are actually any shares avail on a day like today ($4.56), and the associated costs to the short clowns.
Still waiting for our Clown Car dismount...
Be wonderful if this could be updated on a daily basis (maybe hourly during a bear raid). Would do it myself, but have no access to Fidelity data, and only sporadic access to Bloomberg.
Thanks,
OOG
|
|
|
Post by otherottawaguy on Apr 27, 2015 13:20:50 GMT -5
www.gtcbio.com/conferences/diabetes-drug-discovery-development-agendaFEATURED SPEAKER 11:00 Dry Powder Formulations for the Inhalation of Oxyntomodulin Andrea Leone-Bay Vice President Scientific Research Mannkind Obesity is a rapidly becoming a global epidemic and underlies many disease conditions including diabetes and cardiovascular disease. Current treatment options are limited and are challenged by undesirable side effects. Oxyntomodulin (OXY) is an endogenous peptide hormone that signals satiety in healthy individuals. High circulating OXY concentrations are associated with satiety and low OXY concentrations are associated with a feeling of hunger. This activity profile positions OXY as a potential treatment for obesity. To address this unmet medical need, this presentation will introduce an approach to developing an orally inhaled dry powder OXY product administered using a small, breath-powered inhaler for obesity therapy. The audience will learn about oxyntomodulin, a potential new obesity therapy and about the administration of peptides by oral inhalation using a simple, patient-friendly approach
|
|
|
Post by otherottawaguy on Apr 27, 2015 8:10:18 GMT -5
MannKind has added a news release to its Investor Relations website. Title: MannKind to Manufacture 12 Unit Cartridge Strength of AFREZZA(R) Following FDA Approval
Date(s): 27-Apr-2015 9:00 AM
For a complete listing of our news releases, please click here: www.news.mannkindcorp.com/phoenix.zhtml?c=147953&p=irol-newsArticle&ID=2040304
But to save you the time here is the announcement:
Press Releases
Printer Friendly Version View printer-friendly version << Back MannKind to Manufacture 12 Unit Cartridge Strength of AFREZZA(R) Following FDA Approval
VALENCIA, Calif., April 27, 2015 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) today announced that it will begin to manufacture a 12 unit cartridge strength of AFREZZA (insulin human) Inhalation Powder to improve glycemic control in adult patients with diabetes. The 12 unit cartridge was approved by the U.S. Food and Drug Administration on April 17, 2015 and is expected to be launched by Sanofi in the second half of 2015.
The new dosage strength complements the existing 4 unit and 8 unit cartridges and will provide patients with another option to receive their prescribed dose.
About Afrezza®
Afrezza® (insulin human) Inhalation Powder is used to control high blood sugar in adults with type 1 and type 2 diabetes. The drug-device combination product consists of a dry formulation of human insulin delivered in a specially designed inhaler. Administered at the beginning of a meal, Afrezza® delivers insulin into the body through the lungs with peak insulin levels achieved within 12 to 15 minutes. Afrezza® is available in 4-unit and 8-unit single-use cartridges that can be combined to meet the prescribed dose. In addition, the U.S. Food and Drug Administration (FDA) recently approved a 12-unit cartridge strength of insulin powder for Afrezza®. The disposable inhaler can be used to take the cartridges for up to 15 days and does not require cleaning or maintenance.
Sanofi and MannKind have entered into a worldwide exclusive licensing agreement to develop and commercialize Afrezza®. Under the collaboration agreement, Sanofi is responsible for global commercial, regulatory and development activities.
INDICATIONS AND USAGE FOR AFREZZA® (insulin human) Inhalation Powder
Prescription Afrezza® is a man-made rapid acting inhaled insulin breathed through your lungs and is used to control high blood sugar in adults with type 1 and type 2 diabetes.
Limitations of Use: Do not use Afrezza® in place of long-acting insulin; Afrezza® must be used with a long-acting insulin in patients with type 1 diabetes. Do not use Afrezza® to treat diabetic ketoacidosis. It is not known if Afrezza® is safe and effective for use in people who smoke. Afrezza® is not for use in patients who smoke or who have recently stopped smoking (less than 6 months). It is not known if Afrezza® is safe and effective in children under 18 years of age.
Important Safety Information for Afrezza®
WARNING: RISK OF SUDDEN LUNG PROBLEMS (BRONCHOSPASMS) IN PATIENTS WITH LONG-TERM (CHRONIC) LUNG DISEASE Sudden lung problems (acute bronchospasm) have been seen in patients with asthma and COPD (chronic obstructive pulmonary disease) using Afrezza®.
Afrezza® is not to be used in patients with long-term lung disease such as asthma or COPD.
Before initiating Afrezza®, your doctor will perform a detailed medical history, physical examination, and a breathing test (called spirometry) to identify potential lung problems.
Do not use Afrezza® if you have problems with your lungs, such as asthma or COPD (chronic obstructive pulmonary disease). Do not use Afrezza® during a low blood sugar reaction (hypoglycemia). If you are allergic to regular human insulin or to any of the ingredients in Afrezza®, do not use Afrezza® as this may cause a significant and severe allergic reaction.
Before using Afrezza®, it is important to tell your doctor about all your medical conditions, including if you have a history of lung problems, if you smoke or have recently quit smoking, if you are pregnant or plan to become pregnant, or if you are breast feeding or planning to breast-feed. Tell your doctor about all other medicines and supplements you take.
Your doctor will take a medical history, and do a physical exam and a breathing test (called spirometry) to determine if you have lung problems. Patients with lung problems should not use Afrezza®. If your doctor finds you have lung problems, use of Afrezza® may cause a severe asthma-like breathing problem. Afrezza® can reduce lung function, so your doctor will also want to test your breathing 6 months after starting Afrezza®, and then each year after that, even if you have no lung symptoms. More frequent testing should be done if you have symptoms such as wheezing or coughing.
You must test your blood sugar levels while using insulin, such as Afrezza®. Do not make any changes to your dose or type of insulin without talking to your healthcare provider. Any change of insulin should be made carefully and only under your doctor's care.
There are certain serious side-effects that are associated with the use of Afrezza®.
Severe allergic reaction (including whole body reaction) is one of the serious side effects. Get medical help right away if you have any signs or symptoms of a severe allergic reaction,including a rash over your whole body, trouble breathing, a fast heartbeat, or sweating.
Low blood sugar (hypoglycemia) is one of the most common side effects of insulin, including Afrezza®, which can be serious and life-threatening. Common symptoms of hypoglycemia are dizziness or light-headedness, sweating, confusion, headache, blurred vision, slurred speech, shakiness, fast heartbeat, anxiety, irritability or mood change, or hunger. It may cause harm to your heart or brain. It is important for you to understand how to manage the use of Afrezza®, and to understand how to lessen the risk of hypoglycemia events.
Lung cancer occurred in more people who were taking Afrezza® compared to other diabetes medications. There were too few cases to know if lung cancer was related to Afrezza®. Tell your doctor if you currently have lung cancer, have had it in the past, or if you have an increased risk of developing lung cancer.
Heart failure can occur if you are taking insulin together with certain medicines called TZDs (thiazolidinediones), even if you have never had heart failure or other heart problems. If you already have heart failure it may get worse while you take TZDs with Afrezza®. Tell your doctor if you have any new or worsening symptoms of heart failure including shortness of breath, swelling of your ankles or feet or sudden weight gain. Your treatment with Afrezza and TZDs may need to be changed or stopped if you have new or worsening heart failure.
Get emergency help if you have trouble breathing, shortness of breath, fast heartbeat, swelling of your face, tongue, or throat, sweating, extreme drowsiness, dizziness, or confusion.
While using Afrezza do not drive or operate heavy machinery until you know how Afrezza affects you. You should not drink alcohol or use other medicines that contain alcohol and you should not smoke.
The most common side effects of Afrezza® include low blood sugar (hypoglycemia), cough, sore throat, headache, diarrhea, tiredness, and nausea.
Please see full Prescribing Information, including Boxed WARNING, at www.afrezza.com.
Afrezza® is a registered trademark of MannKind Corporation.
About MannKind Corporation
MannKind Corporation (Nasdaq:MNKD) focuses on the discovery and development of therapeutic products for patients with diseases such as diabetes. MannKind maintains a website at www.mannkindcorp.com to which MannKind regularly posts copies of its press releases as well as additional information about MannKind. Interested persons can subscribe on the MannKind website to e-mail alerts that are sent automatically when MannKind issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the website.
Forward-Looking Statements
This press release contains forward-looking statements that involve risks and uncertainties. Words such as "believes", "anticipates", "plans", "expects", "intend", "will", "goal", "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon the Company's current expectations. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, MannKind's dependency on Sanofi for commercialization of Afrezza, manufacturing effectiveness and other risks detailed in MannKind's filings with the Securities and Exchange Commission, including the Annual Report on Form 10-K for the year ended December 31, 2014 and periodic reports on Form 10-Q and Form 8-K. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and MannKind undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this press release. CONTACT: Company Contact: Matthew J. Pfeffer Chief Financial Officer 661-775-5300 mpfeffer@mannkindcorp.com
MannKind Corporation Logo MannKind Corporation
|
|
|
Post by otherottawaguy on Apr 26, 2015 16:05:27 GMT -5
|
|
|
Post by otherottawaguy on Apr 24, 2015 15:21:30 GMT -5
Sorry couldn't find the short interest thread.
Settlement Date, Short Interest, Avg Daily Share Volume, Days To Cover
4/15/2015 96,880,182 3/31/2015 95,717,587 3,373,112 28.376641 3/13/2015 90,882,779 6,976,436 13.027107
Read more: www.nasdaq.com/symbol/mnkd/short-interest#ixzz3YGBA7Nme
OOG
|
|
|
Post by otherottawaguy on Apr 23, 2015 15:31:58 GMT -5
I be happy with a one for one swap of the Berkshire "B"s...
|
|